{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:27:49Z","timestamp":1793946469661,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105512","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:05:19Z","timestamp":1785701119000},"page":"105512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Correlation between ESR1 mutation and PD-L1 expression in breast carcinoma: A narrative review"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0642-2437","authenticated-orcid":false,"given":"Kartavya Kumar","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105512_bib1","article-title":"Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy","volume":"155","author":"Ahmed","year":"2022","journal-title":"Biomed. & Pharmacother. = Biomedecine & Pharmacother."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105512_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad027","article-title":"Estrogen receptor alpha mutations regulate gene expression and cell growth in breast cancer through microRNAs","volume":"5","author":"Arnesen","year":"2023","journal-title":"NAR Cancer"},{"key":"10.1016\/j.critrevonc.2026.105512_bib3","doi-asserted-by":"crossref","unstructured":"Arnesen, S., Polaski, J.T., Blanchard, Z., Osborne, K.S., Welm, A.L., O\u2019Connell, R.M., & Gertz, J. (2023b). Estrogen receptor alpha mutations regulate gene expression and cell growth in breast cancer through microRNAs (p. 2022.10.07.511340). bioRxiv. https:\/\/doi.org\/10.1101\/2022.10.07.511340.","DOI":"10.1101\/2022.10.07.511340"},{"key":"10.1016\/j.critrevonc.2026.105512_bib4","unstructured":"Azvolinsky, A. (2025, September 26). Breast Cancer Patients With ESR1 Mutations Fare Worse | CancerNetwork. https:\/\/www.cancernetwork.com\/view\/breast-cancer-patients-esr1-mutations-fare-worse."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105512_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2026.104324","article-title":"Peptide-mediated immunomodulation of tumor microenvironment in triple-negative breast cancer: A comprehensive review","volume":"393","author":"Bhayo","year":"2026","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105512_bib6","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105512_bib7","article-title":"Hormone therapy enhances anti-PD1 efficacy in premenopausal estrogen receptor-positive and HER2-negative advanced breast cancer","volume":"6","author":"Chen","year":"2025","journal-title":"Cell. Rep. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105512_bib8","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3390\/cancers15041306","article-title":"CDK4\/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients","volume":"15","author":"Crucitta","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105512_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2309693","article-title":"Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer","volume":"20","author":"Dailey","year":"2024","journal-title":"Human. Vaccin. & Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105512_bib10","doi-asserted-by":"crossref","first-page":"6873","DOI":"10.1038\/s41598-024-56412-8","article-title":"Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling","volume":"14","author":"De Marchi","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105512_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: An overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"Npj Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105512_bib12","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.2147\/OTT.S171465","article-title":"The predictive ability of plasma ESR1 mutations for the efficacy of endocrine therapy in hormone-receptor-positive advanced breast cancer","volume":"11","author":"Du","year":"2018","journal-title":"OncoTargets Ther."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105512_bib13","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1002\/cncr.32345","article-title":"ESR1 Mutations in Breast Cancer","volume":"125","author":"Dustin","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105512_bib14","unstructured":"ESR1 Mutations in Hormone Receptor Positive Breast Cancer. (n.d.). College of American Pathologists. Retrieved September 24, 2025, from https:\/\/www.cap.org\/member-resources\/articles\/esr1-mutations-in-hormone-receptor-positive-breast-cancer."},{"key":"10.1016\/j.critrevonc.2026.105512_bib15","doi-asserted-by":"crossref","unstructured":"Fanning, S.W., Mayne, C.G., Dharmarajan, V., Carlson, K.E., Martin, T.A., Novick, S.J., Toy, W., Green, B., Panchamukhi, S., Katzenellenbogen, B.S., Tajkhorshid, E., Griffin, P.R., Shen, Y., Chandarlapaty, S., Katzenellenbogen, J.A., & Greene, G.L. (n.d.). Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. eLife, 5, e12792. https:\/\/doi.org\/10.7554\/eLife.12792.","DOI":"10.7554\/eLife.12792"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105512_bib16","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 Mutations and the Treatment of Estrogen Receptor\u2013Positive Advanced Breast Cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105512_bib17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s42003-025-08054-3","article-title":"Breast cancer patient-derived scaffolds enhance the understanding of PD-L1 regulation and T cell cytotoxicity","volume":"8","author":"Garre","year":"2025","journal-title":"Commun. Biol."},{"issue":"15_","key":"10.1016\/j.critrevonc.2026.105512_bib18","article-title":"ESR1 mutations provide novel targets for breast cancer immunotherapy","volume":"38","author":"Goldberg","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105512_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/2767-9764.CRC-23-0244","article-title":"Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor\u2013positive Breast Cancer","volume":"4","author":"Goldberg","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105512_bib20","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae051","article-title":"Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies","volume":"165","author":"Hancock","year":"2024","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105512_bib21","first-page":"1","article-title":"The regulatory role of CDK4\/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (Review)","volume":"56","author":"He","year":"2025","journal-title":"Int. J. Mol. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105512_bib22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations as a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.critrevonc.2026.105512_bib23","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1200\/JCO.23.02733","article-title":"Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer: Phase Ia\/Ib EMBER Study","volume":"42","author":"Jhaveri","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105512_bib24","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/s41467-022-29498-9","article-title":"ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105512_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41523-022-00426-w","article-title":"Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer","volume":"8","author":"Li","year":"2022","journal-title":"Npj Breast Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105512_bib26","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/0008-5472.CAN-21-2576","article-title":"Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis","volume":"82","author":"Li","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105512_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbrc.2018.09.005","article-title":"ER\u03b1 is a negative regulator of PD-L1 gene transcription in breast cancer","volume":"505","author":"Liu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105512_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13058-025-01962-6","article-title":"Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption","volume":"27","author":"Lopez","year":"2025","journal-title":"Breast Cancer Research BCR"},{"key":"10.1016\/j.critrevonc.2026.105512_bib29","unstructured":"Mediclinic Middle East. (2019). A Phase II Study of Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation (Clinical Trial Registration No. NCT03879174). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03879174."},{"key":"10.1016\/j.critrevonc.2026.105512_bib30","unstructured":"MPH, T.B. (2025, September 26). Exploring New Approaches for ESR1 Mutations in Recent Trials and Future Directions | Targeted Oncology\u2014Immunotherapy, Biomarkers, and Cancer Pathways. https:\/\/www.targetedonc.com\/view\/exploring-new-approaches-for-esr1-mutations-in-recent-trials-and-future-directions."},{"issue":"32","key":"10.1016\/j.critrevonc.2026.105512_bib31","doi-asserted-by":"crossref","first-page":"33972","DOI":"10.18632\/oncotarget.5583","article-title":"High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer","volume":"6","author":"Qin","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105512_bib32","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.18632\/oncotarget.3216","article-title":"Prognostic and predictive value of PDL1 expression in breast cancer","volume":"6","author":"Sabatier","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105512_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.582863","article-title":"Estrogen Receptor Downregulates Expression of PD-1\/PD-L1 and Infiltration of CD8+ T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer","volume":"10","author":"Shuai","year":"2020","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105512_bib34","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat. Genet."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105512_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151851","article-title":"Targeting ESR1 mutation\u2013induced transcriptional addiction in breast cancer with BET inhibition","volume":"7","author":"Udden","year":"2022","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105512_bib36","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1158\/0008-5472.CAN-20-1200","article-title":"Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer","volume":"81","author":"Williams","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105512_bib37","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.2147\/CMAR.S173193","article-title":"Clinical value of circulating <em>ESR1<\/em> mutations for patients with metastatic breast cancer: A meta-analysis","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancer Manag. Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:37:52Z","timestamp":1793943472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"alternative-id":["S1040842826003999"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105512","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation between ESR1 mutation and PD-L1 expression in breast carcinoma: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105512"}}